{"id":"placebo-to-mk-0954a","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NK1 receptor antagonists work by blocking the binding of substance P, a neuropeptide involved in pain transmission and emesis pathways. By inhibiting NK1 receptors, MK-0954A may reduce nausea, vomiting, and potentially pain signaling. This mechanism has been explored for chemotherapy-induced nausea and vomiting (CINV) and other conditions involving substance P dysregulation.","oneSentence":"MK-0954A is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:28:57.910Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV)"}]},"trialDetails":[{"nctId":"NCT00447603","phase":"PHASE3","title":"A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2007-05-24","conditions":"Hypertension","enrollment":40},{"nctId":"NCT01307046","phase":"PHASE3","title":"MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":336},{"nctId":"NCT01307033","phase":"PHASE3","title":"A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":278},{"nctId":"NCT00092209","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-04","conditions":"Hypertension","enrollment":840}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to MK-0954A","genericName":"Placebo to MK-0954A","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MK-0954A is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system. Used for Chemotherapy-induced nausea and vomiting (CINV).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}